Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03733470 · ClinicalTrials.gov registry record · Phase 4
Hypoxic Pulmonary Vasoconstriction Pilot Study
A Phase 4 study, sponsored by Eric A. Hoffman.
- Completed
- Registry status
- Phase 4
- Development phase
- 22
- Enrollment target
NCT03733470 is a Phase 4 study that has completed, run by Eric A. Hoffman. The registered enrollment target is 22 participants.
The verdict
NCT03733470, a Phase 4 study, has completed, sponsored by Eric A. Hoffman.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 22 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the events leading to smoking-associated centrilobular and paraseptal emphysema are caused by a failure of the lungs' inherent mechanisms to block hypoxic pulmonary vasoconstriction (HPV) in areas of smoking-induced inflammation.
Interventions
- DRUG Sildenafil study group
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2011-06-29 |
| Est. Completion | 2014-01-13 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03733470
The ClinicalTrials.gov registry entry for NCT03733470 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eric A. Hoffman, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sildenafil study group is the first listed.
NCT03733470 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03733470 about?
NCT03733470 is a clinical study titled "Hypoxic Pulmonary Vasoconstriction Pilot Study". The purpose of this study is to determine if the events leading to smoking-associated centrilobular and paraseptal emphysema are caused by a failure of the lungs' inherent mechanisms to block hypoxic pulmonary vasoconstriction (HPV) in areas of smoking-induced inflammation.
What is the current status of trial NCT03733470?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 22 participants. The study started on 2011-06-29. Estimated completion is 2014-01-13.
What interventions are being tested in trial NCT03733470?
The interventions under investigation include: Sildenafil study group (DRUG).
Who is sponsoring clinical trial NCT03733470?
This trial is sponsored by Eric A. Hoffman, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.